Following the LEADER – why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes

https://doi.org/10.1016/j.jdiacomp.2016.08.017Get rights and content

Abstract

The field of type 2 diabetes is undergoing a major transformation. Recent cardiovascular outcomes trials of glucose-lowering agents – including EMPA-REG, IRIS and LEADER, have all demonstrated convincing cardiovascular benefits within a relatively short period of time – all likely driven via non-glycemic effects of compounds under study. The implications of these studies (with primary focus on the LEADER trial) – and how their result may be paradigm shifting for type 2 diabetes management, are discussed in this article.

References (19)

  • WC Cushman et al.

    Effects of intensive blood-pressure control in type 2 diabetes mellitus

    The New England Journal of Medicine

    (2010)
  • W Duckworth et al.

    Glucose control and vascular complications in veterans with type 2 diabetes

    The New England Journal of Medicine

    (2009)
  • HC Gerstein et al.

    Effects of intensive glucose lowering in type 2 diabetes

    The New England Journal of Medicine

    (2008)
  • HC Gerstein et al.

    Long-term effects of intensive glucose lowering on cardiovascular outcomes

    The New England Journal of Medicine

    (2011)
  • HN Ginsberg et al.

    Effects of combination lipid therapy in type 2 diabetes mellitus

    The New England Journal of Medicine

    (2010)
  • RA Hayward et al.

    Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

    The New England Journal of Medicine

    (2015)
  • RR Holman et al.

    Sitagliptin and cardiovascular outcomes in type 2 diabetes

    The New England Journal of Medicine

    (2015)
  • RR Holman et al.

    10-year follow-up of intensive glucose control in type 2 diabetes

    The New England Journal of Medicine

    (2008)
  • SE Inzucchi et al.

    Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

    Diabetes Care

    (2015)
There are more references available in the full text version of this article.

Cited by (0)

Conflict of interest: Dr. Kosiborod has received research grants from Astra Zeneca, Gilead Sciences, Genentech and Sanofi, has served as consultant for AstraZeneca, Ely Lilly, Takeda, Amgen, Sanofi, GSK, Boehringer Ingelheim, Novo Nordisk, Merck (Diabetes), ZS Pharma, and Glytec, and participated in speakers bureau for Amgen.

View full text